Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Community
/
United States
/
Pharmaceuticals & Biotech
/
Halozyme Therapeutics
HALO
Halozyme Therapeutics
Biosimilar Competition And Pricing Pressures Will Erode Biologic Margins
AN
AnalystLowTarget
Not Invested
Consensus Narrative from 8 Analysts
Published
18 May 25
Updated
16 Aug 25
1
Set Fair Value
0
votes
Share
AnalystLowTarget
's Fair Value
US$51.00
35.2% overvalued
intrinsic discount
16 Aug
US$68.96
Loading
1Y
11.7%
7D
9.7%
Author's Valuation
US$51.0
35.2% overvalued
intrinsic discount
AnalystLowTarget Fair Value
View Valuation
Narrative
Updates
0
Valuator
Company Info
Notes
AnalystLowTarget Fair Value
US$51.0
35.2% overvalued
intrinsic discount
Future estimation in
3 Years
time period
Past
Future
-120m
2b
2014
2017
2020
2023
2025
2026
2028
Revenue US$1.8b
Earnings US$1.1b
Revenue
Profit Margin
Future PE
Revenue
% p.a.
0
Decrease
Increase
Current revenue growth rate
12.36%
Biotech revenue growth rate
12.71%
Other Inputs & Calculation
Risk Level (Discount Rate)
Our default considers factors like the company's size, volatility, profitablity and country of operation.
Risk Level (Discount Rate)
%
0
Decrease
Increase
Current discount rate
6.95%
Calculation
US$1.06b
Earnings '28
x
5.55x
PE Ratio '28
=
US$5.86b
Market Cap '28
US$5.86b
Market Cap '28
/
94.08m
No. shares '28
=
US$62.34
Share Price '28
US$62.34
Share Price '28
Discounted to 2025 @ 6.95% p.a.
=
US$50.96
Fair Value '25
